Can a lighter chemo punch still knock out lung cancer when paired with immunotherapy?

NCT ID NCT05312840

Completed Disease control Sponsor: People's Hospital of Quzhou Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 4 trial tested two different doses of chemotherapy (standard and low-dose) combined with the immunotherapy drug Sintilimab in 20 people with advanced squamous non-small cell lung cancer. The goal was to see if the lower-dose combination could shrink tumors and control the disease with fewer side effects. Researchers measured response rates, survival, and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cisplatin or Carboplatin, Gemcitabine, and Sintilimab
What this could lead to: If successful, this could show that a lower-dose chemo combination with immunotherapy is just as effective but safer for advanced lung cancer patients.
What could go wrong: This is a very small, completed Phase 4 trial with only 20 participants, so results may not apply broadly. The low-dose approach might not control the cancer as well as standard doses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SQUAMOUS NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma non-small cell squamous lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Quzhou people's Hospital

Quzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.